Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2016 (2016), Article ID 9406319, 8 pages
http://dx.doi.org/10.1155/2016/9406319
Review Article

CEACAM1: Expression and Role in Melanocyte Transformation

1Colentina Clinical Hospital, 1st Dermatology Department, “Carol Davila” University of Medicine and Pharmacy, 020125 Bucharest, Romania
2Department of Pathophysiology II, Clinical Department No. 2, “Carol Davila” University of Medicine and Pharmacy, 021105 Bucharest, Romania
3Pathology Department, Colentina Clinical Hospital, “Carol Davila” University of Medicine and Pharmacy, 020125 Bucharest, Romania
4Department of Medicine, Section of Medical Oncology, Yale University School of Medicine, New Haven, CT 208028, USA

Received 8 April 2016; Revised 7 July 2016; Accepted 25 July 2016

Academic Editor: Simone Ribero

Copyright © 2016 Gabriela Turcu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Zurac, M. Neagu, C. Constantin et al., “Variations in the expression of TIMP1, TIMP2 and TIMP3 in cutaneous melanoma with regression and their possible function as prognostic predictors,” Oncology Letters, vol. 11, no. 5, pp. 3354–3360, 2016. View at Publisher · View at Google Scholar
  2. H. M. Kluger, K. Hoyt, A. Bacchiocchi et al., “Plasma markers for identifying patients with metastatic melanoma,” Clinical Cancer Research, vol. 17, no. 8, pp. 2417–2425, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Markel, R. Ortenberg, R. Seidman et al., “Systemic dysregulation of CEACAM1 in melanoma patients,” Cancer Immunology, Immunotherapy, vol. 59, no. 2, pp. 215–230, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Sang, L. Wang, C. Ding et al., “Melanoma-associated antigen genes—an update,” Cancer Letters, vol. 302, no. 2, pp. 85–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. M. S. Lawrence, P. Stojanov, P. Polak et al., “Mutational heterogeneity in cancer and the search for new cancer-associated genes,” Nature, vol. 499, no. 7457, pp. 214–218, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Neagu, “The immune system—a hidden treasure for biomarker discovery in cutaneous melanoma,” Advances in Clinical Chemistry, vol. 58, pp. 89–140, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Neagu, C. Constantin, and S. Zurac, “Immune parameters in the prognosis and therapy monitoring of cutaneous melanoma patients: experience, role, and limitations,” BioMed Research International, vol. 2013, Article ID 107940, 13 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Bulman, M. Neagu, and C. Constantin, “Immunomics in skin cancer—improvement in diagnosis, prognosis and therapy monitoring,” Current Proteomics, vol. 10, no. 3, pp. 202–217, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Neagu, C. Constantin, and C. Longo, “Chemokines in the melanoma metastasis biomarkers portrait,” Journal of Immunoassay and Immunochemistry, vol. 36, no. 6, pp. 559–566, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Edward, “Integrins and other adhesion molecules involved in melanocytic tumor progression,” Current Opinion in Oncology, vol. 7, no. 2, pp. 185–191, 1995. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Nagaishi, H. Iijima, A. Nakajima, D. Chen, and R. S. Blumberg, “Role of CEACAM1 as a regulator of T cells,” Annals of the New York Academy of Sciences, vol. 1072, pp. 155–175, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. A. L. Servin, “Pathogenesis of Afa/Dr diffusely adhering Escherichia coli,” Clinical Microbiology Reviews, vol. 18, no. 2, pp. 264–292, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Huang, J. D. Hardy, Y. Sun, and J. E. Shively, “Essential role of biliary glycoprotein (CD66a) in morphogenesis of the human mammary epithelial cell line MCF10F,” Journal of Cell Science, vol. 112, part 23, pp. 4193–4205, 1999. View at Google Scholar · View at Scopus
  14. F. Prall, P. Nollau, M. Neumaier et al., “Cd66a (BGP), an adhesion molecule of the carcinoembryonic antigen family, is expressed in epithelium, endothelium, and myeloid cells in a wide range of normal human tissues,” Journal of Histochemistry and Cytochemistry, vol. 44, no. 1, pp. 35–41, 1996. View at Publisher · View at Google Scholar · View at Scopus
  15. S. D. Gray-Owen and R. S. Blumberg, “CEACAM1: contact-dependent control of immunity,” Nature Reviews Immunology, vol. 6, no. 6, pp. 433–446, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Markel, D. Wolf, J. Hanna et al., “Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions,” The Journal of Clinical Investigation, vol. 110, no. 7, pp. 943–953, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. V. M. Morales, A. Christ, S. M. Watt et al., “Regulation of human intestinal intraepithelial lymphocyte cytolytic function by biliary glycoprotein (CD66a),” Journal of Immunology, vol. 163, no. 3, pp. 1363–1370, 1999. View at Google Scholar · View at Scopus
  18. A. Nakajima, H. Iijima, M. F. Neurath et al., “Activation-induced expression of carcinoembryonic antigen-cell adhesion molecule 1 regulates mouse T lymphocyte function,” Journal of Immunology, vol. 168, no. 3, pp. 1028–1035, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. A. W. Horne, J. O. White, and E.-N. Lalani, “Adhesion molecules and the normal endometrium,” BJOG: An International Journal of Obstetrics and Gynaecology, vol. 109, no. 6, pp. 610–617, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Beauchemin and A. Arabzadeh, “Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis,” Cancer and Metastasis Reviews, vol. 32, no. 3-4, pp. 643–671, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Chen, H. Iijima, T. Nagaishi et al., “Carcinoembryonic antigen-related cellular adhesion molecule 1 isoforms alternatively inhibit and costimulate human T cell function,” The Journal of Immunology, vol. 172, no. 6, pp. 3535–3543, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Iijima, M. F. Neurath, T. Nagaishi et al., “Specific regulation of T helper cell 1-mediated murine colitis by CEACAM1,” The Journal of Experimental Medicine, vol. 199, no. 4, pp. 471–482, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Nagaishi, L. Pao, S.-H. Lin et al., “SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms,” Immunity, vol. 25, no. 5, pp. 769–781, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. S. C. Stocks, M.-H. Ruchaud-Sparagano, M. A. Kerr, F. Grunert, C. Haslett, and I. Dransfield, “CD66: role in the regulation of neutrophil effector function,” European Journal of Immunology, vol. 26, no. 12, pp. 2924–2932, 1996. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Markel, R. Seidman, Y. Cohen et al., “Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack,” Immunology, vol. 126, no. 2, pp. 186–200, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Wagener and S. Ergün, “Angiogenic properties of the carcinoembryonic antigen-related cell adhesion molecule 1,” Experimental Cell Research, vol. 261, no. 1, pp. 19–24, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. S. M. Najjar, “Regulation of insulin action by CEACAM1,” Trends in Endocrinology and Metabolism, vol. 13, no. 6, pp. 240–245, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. C. R. Hauck, “Cell adhesion receptors—signaling capacity and exploitation by bacterial pathogens,” Medical Microbiology and Immunology, vol. 191, no. 2, pp. 55–62, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Yang, C. K. Li, K. Li et al., “Hematological findings in SARS patients and possible mechanisms (review),” International Journal of Molecular Medicine, vol. 14, no. 2, pp. 311–315, 2004. View at Google Scholar · View at Scopus
  30. C. Houde, S. Roy, N. Leung, D. W. Nicholson, and N. Beauchemin, “The cell adhesion molecule CEACAM1-L is a substrate of caspase-3-mediated cleavage in apoptotic mouse intestinal cells,” The Journal of Biological Chemistry, vol. 278, no. 19, pp. 16929–16935, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. B. B. Singer, E. Klaile, I. Scheffrahn et al., “CEACAM1 (CD66a) mediates delay of spontaneous and Fas ligand-induced apoptosis in granulocytes,” European Journal of Immunology, vol. 35, no. 6, pp. 1949–1959, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Nittka, C. Böhm, H. Zentgraf, and M. Neumaier, “The CEACAM1-mediated apoptosis pathway is activated by CEA and triggers dual cleavage of CEACAM1,” Oncogene, vol. 27, no. 26, pp. 3721–3728, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Thies, A. Berlin, G. Brunner et al., “Glycoconjugate profiling of primary melanoma and its sentinel node and distant metastases: implications for diagnosis and pathophysiology of metastases,” Cancer Letters, vol. 248, no. 1, pp. 68–80, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. I. Thöm, O. Schult-Kronefeld, I. Burkholder et al., “Expression of CEACAM-1 in pulmonary adenocarcinomas and their metastases,” Anticancer Research, vol. 29, no. 1, pp. 249–254, 2009. View at Google Scholar · View at Scopus
  35. L. Cancer, W. Sienel, S. Dango et al., “Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 promotes progression of non-small cell,” Clinical Cancer Research, vol. 9, no. 6, pp. 2260–2266, 2003. View at Google Scholar
  36. M. Neumaier, S. Paululat, A. Chan, P. Matthaes, and C. Wagener, “Biliary glycoprotein, a potential human cell adhesion molecule, is down-regulated in colorectal carcinomas,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 22, pp. 10744–10748, 1993. View at Publisher · View at Google Scholar · View at Scopus
  37. W. Luo, M. Tapolsky, K. Earley et al., “Tumor-suppressive activity of CD66a in prostate cancer,” Cancer Gene Therapy, vol. 6, no. 4, pp. 313–321, 1999. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Riethdorf, B. W. Lisboa, U. Henkel, M. Naumann, C. Wagener, and T. Löning, “Differential expression of CD66a (BGP), a cell adhesion molecule of the carcinoembryonic antigen family, in benign, premalignant, and malignant lesions of the human mammary gland,” Journal of Histochemistry and Cytochemistry, vol. 45, no. 7, pp. 957–963, 1997. View at Publisher · View at Google Scholar · View at Scopus
  39. G. Markel, N. Lieberman, G. Katz et al., “CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity,” The Journal of Immunology, vol. 168, no. 6, pp. 2803–2810, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. G. Markel, H. Mussaffi, K.-L. Ling et al., “The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients,” Blood, vol. 103, no. 5, pp. 1770–1778, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. G. Markel, R. Seidman, N. Stern et al., “Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions,” Journal of Immunology, vol. 177, no. 9, pp. 6062–6071, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Thies, I. Moll, J. Berger et al., “CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease,” Journal of Clinical Oncology, vol. 20, no. 10, pp. 2530–2536, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Ebrahimnejad, T. Streichert, P. Nollau et al., “CEACAM1 enhances invasion and migration of melanocytic and melanoma cells,” The American Journal of Pathology, vol. 165, no. 5, pp. 1781–1787, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. J. Liu, G. Di, C.-T. Wu, X. Hu, and H. Duan, “CEACAM1 inhibits cell-matrix adhesion and promotes cell migration through regulating the expression of N-cadherin,” Biochemical and Biophysical Research Communications, vol. 430, no. 2, pp. 598–603, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. N. Ullrich, S. Löffek, S. Horn et al., “MITF is a critical regulator of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in malignant melanoma,” Pigment Cell and Melanoma Research, vol. 28, no. 6, pp. 736–740, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. J. W. Foster, “Mutations in SOX9 cause both autosomal sex reversal and campomelic dysplasia,” Acta Paediatrica Japonica, vol. 38, no. 4, pp. 405–411, 1996. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Passeron, J. C. Valencia, C. Bertolotto et al., “SOX9 is a key player in ultraviolet B-induced melanocyte differentiation and pigmentation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 35, pp. 13984–13989, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Passeron, J. C. Valencia, T. Namiki et al., “Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid,” The Journal of Clinical Investigation, vol. 119, no. 4, pp. 954–963, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. O. Shakhova, P. Cheng, P. J. Mishra et al., “Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanoma,” PLoS Genetics, vol. 11, no. 1, Article ID e1004877, 2015. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Zalzali, C. Naudin, P. Bastide et al., “CEACAM1, a SOX9 direct transcriptional target identified in the colon epithelium,” Oncogene, vol. 27, no. 56, pp. 7131–7138, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. B. Fournès, S. Sadekova, C. Turbide, S. Létourneau, and N. Beauchemin, “The CEACAM1-L Ser503 residue is crucial for inhibition of colon cancer cell tumorigenicity,” Oncogene, vol. 20, no. 2, pp. 219–230, 2001. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Ashkenazi, R. Ortenberg, M. Besser, and J. Schachter, “SOX9 indirectly regulates CEACAM1 expression and immune resistance in melanoma cells,” Oncotarget, vol. 7, no. 21, pp. 30166–30177, 2016. View at Publisher · View at Google Scholar
  53. R. Ortenberg, G. Galore-Haskel, I. Greenberg et al., “CEACAM1 promotes melanoma cell growth through Sox-2,” Neoplasia, vol. 16, no. 5, pp. 451–460, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. P.-L. Chen, W.-S. Chen, J. Li, A. C. Lind, and D. Lu, “Diagnostic utility of neural stem and progenitor cell markers nestin and SOX2 in distinguishing nodal melanocytic nevi from metastatic melanomas,” Modern Pathology, vol. 26, no. 1, pp. 44–53, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. S. D. Girouard, A. C. Laga, M. C. Mihm et al., “SOX2 contributes to melanoma cell invasion,” Laboratory Investigation, vol. 92, no. 3, pp. 362–370, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. T. Gambichler, S. Grothe, S. Rotterdam, P. Altmeyer, and A. Kreuter, “Protein expression of carcinoembryonic antigen cell adhesion molecules in benign and malignant melanocytic skin lesions,” American Journal of Clinical Pathology, vol. 131, no. 6, pp. 782–787, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. K. Egawa, Y. Honda, M. Kuroki, and T. Ono, “The carcinoembryonic antigen (CEA) family (CD66) expressed in melanocytic naevi is not expressed in blue naevuscell naevi in dendritic type,” Journal of Cutaneous Pathology, vol. 27, no. 7, pp. 351–358, 2000. View at Publisher · View at Google Scholar · View at Scopus
  58. N. Khatib, J. Pe'er, R. Ortenberg et al., “Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1) in posterior uveal melanoma: correlation with clinical and histological survival markers,” Investigative Ophthalmology and Visual Science, vol. 52, no. 13, pp. 9368–9372, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. W. Sienel, S. Dango, U. Woelfle et al., “Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 promotes progression of non-small cell lung cancer,” Clinical Cancer Research, vol. 9, no. 6, pp. 2260–2266, 2003. View at Google Scholar · View at Scopus
  60. S. Sapoznik, R. Ortenberg, J. Schachter, and G. Markel, “CEACAM1 in malignant melanoma: a diagnostic and therapeutic target,” Current Topics in Medicinal Chemistry, vol. 12, no. 1, pp. 3–10, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. E. Klaile, M. M. Müller, C. Kannicht, B. B. Singer, and L. Lucka, “CEACAM1 functionally interacts with filamin A and exerts a dual role in the regulation of cell migration,” Journal of Cell Science, vol. 118, part 23, pp. 5513–5524, 2005. View at Publisher · View at Google Scholar · View at Scopus
  62. D. Zippel, H. Barlev, R. Ortenberg, I. Barshack, J. Schachter, and G. Markel, “A longitudinal study of CEACAM1 expression in melanoma disease progression,” Oncology Reports, vol. 33, no. 3, pp. 1314–1318, 2015. View at Publisher · View at Google Scholar · View at Scopus
  63. D. J. Karimipour, L. Lowe, L. Su et al., “Standard immunostains for melanoma in sentinel lymph node specimens: which ones are most useful?” Journal of the American Academy of Dermatology, vol. 50, no. 5, pp. 759–764, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. L. L. Yu, T. J. Flotte, K. K. Tanabe et al., “Detection of microscopic melanoma metastases in sentinel lymph nodes,” Cancer, vol. 86, no. 4, pp. 617–627, 1999. View at Publisher · View at Google Scholar · View at Scopus
  65. R. Ortenberg, Y. Sapir, L. Raz et al., “Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions,” Molecular Cancer Therapeutics, vol. 11, no. 6, pp. 1300–1310, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. https://www.pipelinereview.com/index.php/2015072058419/More-News/Agenus-Acquires-Novel-Antibodies-to-Immuno-oncology-Target-CEACAM1.html.
  67. 2016, https://clinicaltrials.gov/.
  68. D. Weinstein, J. Leininger, C. Hamby, and B. Safai, “Diagnostic and prognostic biomarkers in melanoma,” Journal of Clinical and Aesthetic Dermatology, vol. 7, no. 6, pp. 13–24, 2014. View at Google Scholar · View at Scopus
  69. M. Deichmann, A. Benner, M. Bock et al., “S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma,” Journal of Clinical Oncology, vol. 17, no. 6, pp. 1891–1896, 1999. View at Google Scholar · View at Scopus
  70. F. Egberts, W. N. Hitschler, M. Weichenthal, and A. Hauschild, “Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse,” Melanoma Research, vol. 19, no. 1, pp. 31–35, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. S. S. Agarwala, U. Keilholz, E. Gilles et al., “LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951),” European Journal of Cancer, vol. 45, no. 10, pp. 1807–1814, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. R. Harpio and R. Einarsson, “S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma,” Clinical Biochemistry, vol. 37, no. 7, pp. 512–518, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Sivan, F. Suzan, O. Rona et al., “Serum CEACAM1 correlates with disease progression and survival in malignant melanoma patients,” Clinical and Developmental Immunology, vol. 2012, Article ID 290536, 8 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus